62924-61-2

Usage

Uses

Used in Pharmaceutical Synthesis:
N-(2-Chloroethyl)-benzylamine is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Production:
N-(2-Chloroethyl)-benzylamine serves as a crucial component in the production of agrochemicals, aiding in the creation of effective pesticides and other agricultural products to protect crops and enhance yields.
Used in Polymer and Resin Manufacturing:
N-(2-Chloroethyl)-benzylamine is utilized in the manufacturing process of certain polymers and resins, playing a role in the formation of materials with specific properties for various industrial applications.
Used as a Reagent in Organic Chemistry:
In the realm of organic chemistry, N-(2-Chloroethyl)-benzylamine is employed as a reagent, particularly for the formation of amine-based compounds, facilitating a range of chemical reactions and syntheses.

InChI:InChI=1/C9H12ClN/c1-2-11-7-8-5-3-4-6-9(8)10/h3-6,11H,2,7H2,1H3

Upstream product

• 66896-65-9 2-chloro-N-ethyl-benzamide 
• 611-19-8 1-chloro-2-(chloromethyl)benzene 
• 75-04-7 ethylamine 

Downstream Products

• 209416-24-0 N-(2'-chlorophenylmethyl)-N-ethyl-4-(2,4,6-trimethyphenyl)-1-phthalazinamine 
• 664339-14-4 {2-[(2-chloro-benzyl)-ethyl-amino]-ethyl}carbamic acid benzyl ester 
• 55245-84-6 C₁₀H₁₁Cl₂NO 

Relevant academic research and scientific papers

TACHYKININ RECEPTOR ANTAGONISTS

The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.

NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES

The invention relates to novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including proc

Central cholinergic agents. I. Potent acetylcholinesterase inhibitors, 2-[ω-[N-alkyl-N-(ω-phenylalkyl)amino]alkyl]-1H-isoindole-1,3(2H)-dion es, based on a new hypothesis of the enzyme's active site

It has been suggested that the active site of acetylcholinesterase contains a hydrophobic binding site (HBS-1), which is closely adjacent to both the anionic and the esteratic sites. In this paper, we assumed that there exists another hydrophobic binding site (HBS-2), some distance removed from the anionic site. On this assumption, a new working hypothesis was proposed for the design of acetylcholinesterase inhibitors. A series of 2-[ω-[N-alkyl-N-(ω-phenylalkyl)amino]alkyl]-1H-isoindole-1,3(2H)-dion es was designed based on this hypothesis and tested for its inhibitory activities on acetylcholinesterase. Some in this series were revealed to be more potent than physostigmine. Optimum activity was found to be associated with a five carbon chain length separating the benzylamino group from the 1H-isoindole-1,3(2H)-dione (phthalimide) moiety. Quantitative study of substitution effect on the phthalimide moiety revealed that hydrophilic and electron-withdrawing groups enhance the activity.